The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

CEO Robert Blum is “very clear” that the company, which is on track for U.S. approval in September for aficamten to treat a ...

with results expected in the first half of this year as may potentially support the use of aficamten as monotherapy," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "In ...

with results expected in the first half of this year as may potentially support the use of aficamten as monotherapy,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “In ...

Cytokinetics is on track to complete its New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. This timeline is ahead of many investors ...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to ...

CK-4015089 is under clinical development by Cytokinetics and currently in Phase I for Muscular Dystrophy. According to GlobalData, Phase I drugs for Muscular Dystrophy does not have sufficient ...

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate of ...

Cytokinetics Inc is a biopharmaceutical company. It is engaged in the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of ...

Henry C Blum, 73, of Croton on Hudson, NY & former Tivoli resident passed away on December 30, 2024. Born on August 14, 1951 in the Bronx, NY to the late Francis Joseph and Margaret Mary (Cervini ...